CLGN on Nasdaq

CollPlant Biotechnologies Ltd

CollPlant Biotechnologies Ltd is an orthopedic company, listed on Nasdaq (CLGN).1

Price unavailable

Last updated Oct 20, 2026.

Overview

$2.4MRevenue, fiscal 20252
-$11.5MNet income, fiscal 20252

Compare with ENvue Medical, Inc., NutriBand Inc. or Anteris Technologies Global Corp., or pick any stock.

  • TickerCLGN on Nasdaq1
  • IndustryOrthopedic, Prosthetic & Surgical Appliances & Supplies1
  • HeadquartersL31
  • Incorporated inIsrael3
  • Business address4 Oppenheimer St., 11Th Floor, Rehovot, L3 741403
  • Filer categoryNon-accelerated filer3
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

CollPlant Ltd. owns all of our intellectual property. CollPlant Ltd. holds all of the issued and outstanding shares of CollPlant Inc.4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

64.8%Gross margin2
-484.3%Operating margin2
-484.6%Net margin2
360.4%Revenue growth, 20252
-188.9%Return on equity2
-$9.4MFree cash flow2

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Products and services

Revenues From Milestones brought in 84% of the revenue CollPlant Biotechnologies Ltd broke down this way in fiscal 2025.

  1. Revenues From Milestones$2.0M284%
  2. Revenues From Sales Of Goods$371.0K216%down 28% from 2024
Products and services by year
Products and services202320242025
Revenues From Milestones$10.0M$2.0M
Revenues From Sales Of Goods$959.0K$515.0K$371.0K

Regions

United States brought in 92% of the revenue CollPlant Biotechnologies Ltd broke down this way in fiscal 2025.

  1. United States$2.2M292%up 350% from 2024
  2. Europe and Other$98.0K24%
  3. CA [member]$96.0K24%
  4. Israel$1.0K20%down 97% from 2024
Regions by year
Regions202320242025
United States$10.8M$484.0K$2.2M
Europe and Other$28.0K$98.0K
CA [member]$87.0K$96.0K
Israel$5.0K$31.0K$1.0K

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue9¢$835.0K
  • Research and development91¢$8.2M

Out of $2.4M in revenue.2 The company lost money this year.

Financial statements

Revenue567892$2.4M in 2025−53% since 2018
0$5.0M$10.0M$15.0M$20.0M2018: $5.0M$5.0M20182019: $2.3M$2.3M2019−54%2020: $6.1M$6.1M2020+165%2021: $15.6M$15.6M2021+155%2022: $299.0K$299.0K2022−98%2023: $11.0M$11.0M2023+3565%2024: $515.0K$515.0K2024−95%2025: $2.4M$2.4M2025+360%
Gross profit567892$1.5M in 2025−54% since 2018
-$5.0M0$5.0M$10.0M$15.0M2018: $3.4M$3.4M20182019: $439.0K$439.0K2019−87%2020: $3.1M$3.1M2020+614%2021: $13.6M$13.6M2021+335%2022: -$101.0K-$101.0K20222023: $9.0M$9.0M20232024: -$1.1M-$1.1M20242025: $1.5M$1.5M2025
Operating income567892-$11.5M in 2025+171% since 2018
-$20.0M-$15.0M-$10.0M-$5.0M0$5.0M2018: -$4.2M-$4.2M20182019: -$7.6M-$7.6M2019+80%2020: -$5.6M-$5.6M2020−27%2021: $65.0K$65.0K20212022: -$17.1M-$17.1M20222023: -$7.5M-$7.5M2023−56%2024: -$17.3M-$17.3M2024+130%2025: -$11.5M-$11.5M2025−33%
Net income567892-$11.5M in 2025+84% since 2018
-$20.0M-$15.0M-$10.0M-$5.0M0$5.0M2018: -$6.2M-$6.2M20182019: -$11.2M-$11.2M2019+79%2020: -$5.8M-$5.8M2020−48%2021: $237.0K$237.0K20212022: -$16.9M-$16.9M20222023: -$7.0M-$7.0M2023−59%2024: -$16.6M-$16.6M2024+137%2025: -$11.5M-$11.5M2025−31%

Every line of the income statement as filed: the last 3 fiscal years, latest first.2

Period ending2025-12-312024-12-312023-12-31
Revenues$2.4M$515.0K$11.0M
Cost of revenues$835.0K$1.6M$2.0M
Gross profit (loss)$1.5M-$1.1M$9.0M
Research and development$8.2M$10.5M$10.5M
General, administrative and marketing$4.8M$5.6M$6.0M
Total operating loss-$11.5M-$17.3M-$7.5M
Financial income (expenses), net-$6.0K$642.0K$493.0K
Net loss-$11.5M-$16.6M-$7.0M
Basic net loss per ordinary share (in Dollars per share)-$0.94-$1.45-$0.62
Diluted net loss per ordinary share (in Dollars per share)-$0.94-$1.45-$0.62
Weighted average number of ordinary shares used in computation of basic net loss per share (in Shares)12.2M shares11.5M shares11.4M shares
Weighted average number of ordinary shares used in computation of diluted net loss per share (in Shares)12.2M shares11.5M shares11.4M shares

Compare CollPlant Biotechnologies Ltd with another company

Corporate structure

CollPlant Biotechnologies Ltd sits at the top of its group. 1 entity on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of CollPlant Biotechnologies Ltd

  • Ami Sagy Filed SCHEDULE 13G on CollPlant Biotechnologies Ltd, latest Oct 8, 2026 (3 filings since Nov 28, 2025)
  • Lilian S. Loewenbaum Filed SCHEDULE 13D/A on CollPlant Biotechnologies Ltd, latest Aug 21, 2026 (10 filings since Feb 23, 2022)
  • Roumell Asset Management, LLC Filed SC 13G/A on CollPlant Biotechnologies Ltd, latest Feb 13, 2024 (2 filings since Feb 13, 2023)
  • Meitav Investment House Ltd Filed SC 13G/A on CollPlant Biotechnologies Ltd, latest Jul 24, 2023 (3 filings since Feb 2, 2022)
  • INVESTMENT MANAGEMENT OF VIRGINIA LLC Filed SC 13G/A on CollPlant Biotechnologies Ltd, latest Jan 30, 2023 (2 filings since Jan 31, 2022)
  • Reginald J. Hargrove Filed SC 13G/A on CollPlant Biotechnologies Ltd, latest Feb 24, 2022
  • CollPlant Biotechnologies Ltd L3

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What CollPlant Biotechnologies Ltd reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$9.3M2 Dec 31, 2025$9.3M2 Dec 31, 2024+0.3%
Accumulated depreciation$7.9M2 Dec 31, 2025$7.0M2 Dec 31, 2024+12.2%
Property and equipment, net$1.5M2 Dec 31, 2025$2.3M2 Dec 31, 2024−36.1%
Operating-lease assets (leased space)$2.4M2 Dec 31, 2025$3.0M2 Dec 31, 2024−18.9%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$5.6M2 Dec 31, 2025$11.9M2 Dec 31, 2024−53.1%

Intangibles and goodwill

ItemLatestA year beforeChange
Intangible assets, net (excluding goodwill)$73.0K2 Dec 31, 2025$131.0K2 Dec 31, 2024−44.3%

Inventory

ItemLatestA year beforeChange
Inventory, total$573.0K2 Dec 31, 2025$440.0K2 Dec 31, 2024+30.2%
Work in process$283.0K2 Dec 31, 2025$286.0K2 Dec 31, 2024−1.0%
Finished goods$290.0K2 Dec 31, 2025$154.0K2 Dec 31, 2024+88.3%

Leadership

Who has led CollPlant Biotechnologies Ltd, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Eran Rotem2026
  2. Yehiel Tal2026–now

Chief financial officer

  1. Eran Rotem2026–now
Board members and other officers (9)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • Vice President, Research and DevelopmentElana Gazal named Jun 4, 202521
  • Vice President, Human ResourcesHadas Dreiher Horowitz named Jun 4, 202521
  • DirectorAbraham Havron named Feb 17, 2026 to Jul 20, 202622
  • DirectorHugh Evans named Feb 17, 2026 to Jul 20, 202622
  • DirectorJoseph Zarzewsky named Feb 17, 2026 to Jul 20, 202622
  • DirectorAbraham Dreiher Havron named Jun 4, 202521
  • DirectorHugh Dreiher Evans named Jun 4, 202521
  • DirectorJoseph Dreiher Zarzewsky named Jun 4, 202521
  • DirectorRoger Dreiher Pomerantz named Jun 4, 202521

Former names

  • CollPlant Biotechnologies Ltd.Jun 20, 2019 to Jun 20, 20193
  • CollPlant Holdings Ltd.Feb 20, 2015 to Jun 6, 20193

Timeline

  1. Mar 19, 2026New chief executive Yehiel Tal becomes CEO12
  2. Mar 18, 2026New chief executive Eran Rotem becomes CEO11

Calendar

Coming up

  1. Nov 25, 2026Reports results for the quarter ending Sep/202623

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

167 filings to the SEC since October 2021: 5 annual reports, 13 insider forms, 21 large holders, 3 private raises, 125 other. The latest 20:

  1. Oct 15, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  2. Oct 9, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  3. Oct 8, 2026SCHEDULE 13G EDGAR
  4. Oct 8, 2026SCHEDULE 13D/A EDGAR
  5. Oct 6, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  6. Sep 30, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  7. Sep 24, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  8. Sep 22, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  9. Sep 18, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  10. Sep 8, 20264 OWNERSHIP DOCUMENT EDGAR
  11. Sep 8, 20264 OWNERSHIP DOCUMENT EDGAR
  12. Sep 4, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  13. Sep 3, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  14. Sep 1, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  15. Aug 31, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  16. Aug 21, 2026SCHEDULE 13D/A EDGAR
  17. Aug 18, 20266-K EDGAR
  18. Aug 6, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  19. Jul 31, 2026SCHEDULE 13D/A EDGAR
  20. Jul 29, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR

The 167 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Jul 6, 2026Raised $10.4 million in a private offering of equity Form D: 5 investors so far Form D
  2. Feb 4, 2026Raised $4 million in a private offering of equity Form D: 8 investors so far Form D
  3. May 29, 2025Raised $3.9 million in a private offering of securities Form D: 4 investors so far Form D

SEC filer profile

How CollPlant Biotechnologies Ltd is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARCollPlant Biotechnologies Ltd1
  • CIK0001631487
  • Filer statusNon-accelerated filer not an emerging growth company; not a shell company4
  • Incorporated inIsrael4
  • Fiscal year endsDecember 311
  • Industry code (SIC)3842 Orthopedic, Prosthetic & Surgical Appliances & Supplies1
  • SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance1
  • Business address4 Oppenheimer St., 11Th Floor, Rehovot, L3 741401
  • Phone972-73-232-56001
  • Shares outstanding12,803,006 shares as of Dec 31, 20254
  • AuditorKost Forer Gabbay & Kasierer, Tel-Aviv, Israel PCAOB ID 1281; no auditor attestation of internal control over financial reporting4
  • On EDGAR sinceFeb 20, 20151
  • Filings348 in all: 6-K (195), SC 13G/A (16), UPLOAD (13), CORRESP (12), EFFECT (12), 3 (11), 20-F (9), F-1/A (7)1
    All 33 form types

    SCHEDULE 13D/A (7), 424B3 (6), D (6), SC 13G (6), F-3 (5), S-8 (5), 144 (4), CT ORDER (4), F-1 (4), 424B5 (3), DRS/A (3), SC 13D/A (3), 4 (2), DRS (2), DRSLTR (2), POS AM (2), 8-A12B (1), CERT (1), DEL AM (1), F-3/A (1), F-6 (1), SC 13D (1), SCHEDULE 13D (1), SCHEDULE 13G (1), SCHEDULE 13G/A (1)

  • Latest filingsAnnual report (20-F) Mar 26, 2026

Securities registered for trading

ClassSymbolExchange
Ordinary shares, par value NIS 1.50 per shareCLGNNasdaq

From the cover page of the 20-F filed Mar 26, 2026 (Section 12(b) of the Exchange Act).4

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29